Press Releases

Umecrine Cognition presents data supporting a new predictive biomarker in patients with primary biliary cholangitis at the AASLD International Liver Meeting 2021

STOCKHOLM – Umecrine Cognition AB today announces new scientific results for its drug candidate golexanolone, linking the drug target allopregnanolone to cognitive symptoms in patients with primary biliary cholangitis. The data will be presented at The Liver Meeting Digital ExperienceTM 2021, the premier Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), being held November 12-15.

Umecrine Cognition to present at two scientific conferences on the importance of neurosteroids in cognitive dysfunction associated with liver disease

STOCKHOLM – October 6, 2021. Umecrine Cognition AB, whose novel orally-active GABAA receptor modulating steroid antagonist, golexanolone, is in clinical development for hepatic encephalopathy (HE) and other CNS-related disorders, will present at two upcoming meetings pertaining to the potential benefit of golexanolone for cognitive abnormalities in patients with liver disease.

Umecrine Cognition CEO Magnus Doverskog to present at Vator Securities Healthcare Innovation Summit

STOCKHOLM. Umecrine Cognition announced today that CEO Magnus Doverskog will present at Healthcare Innovation Summit on October 7, 2021. Vator Securities Healthcare Innovation Summit is a digital investor event including some of the most innovative and fastest growing companies in the healthcare sector. The event will include focused insights into these healthcare companies, including fire side chats and panel discussions with experts within healthcare and healthcare investments.